eCOA Trials, Delivered Faster without the Trade-offs

TrialMax® combines the flexibility to handle complex study designs with the delivery timelines sponsors expect, so there is no longer a choice between capability and speed.

DISCUSS YOUR PROTOCOL

Faster eCOA. For Every Study.

Sponsors have historically associated TrialMax®, our industry-leading eCOA platform, with advanced capability: the configurability to handle complex scales, bespoke instruments, and demanding study designs. What has changed is the speed at which that capability is delivered. Signant's faster eCOA initiative has compressed timelines across the full study range, from simple studies to the most complex, so sponsors no longer have to weigh platform capability against delivery speed.
Man using laptop

What Faster eCOA Looks Like in Practice

Signant's faster eCOA initiative has fundamentally changed how TrialMax studies are designed and built. Enhanced design tools, automation that accelerates implementation specialist activities without removing their oversight, and an expanded library of validated instruments and translations have together compressed the time from study kick-off to UAT. Simple studies can now be delivered to UAT in as few as 15 working days. For studies ranging through to complex, the range runs to under 5 weeks. 

The capability that makes TrialMax the right choice for all eCOA studies has not changed. The time it takes to deliver has.

Speed Without Compromise

No Capability Gaps

Where other platforms require sponsors to simplify their study design to fit within the constraints of a rigid configuration environment, TrialMax does not. Detailed body maps for tender and swollen joint counts, independent concurrent bleed tracking in hemophilia studies, country-specific concomitant medication diaries, complex food intake diaries, and branching logic with complex scoring algorithms are all deliverable.

The result is a platform that does not ask sponsors to choose. Studies can be as complex as the protocol requires, and delivered on a timeline that meets industry expectations.

No Capability Gaps

Built on a Foundation That Speeds Up Every Study

The timeline improvements in TrialMax are not the result of cutting corners on quality or scientific rigor. They reflect a series of structural changes to how studies are designed and built. Enhanced design tooling gives implementation specialists greater efficiency. Automation handles repeatable tasks at speed while keeping specialist oversight in place. The validated instrument and translation library means content that would previously have required commissioning is often available for immediate reuse. 
Built on a Foundation That Speeds Up Every Study

Faster timelines, same quality, no functionality compromises.

Man using tablet

 

Let's discuss your protocol

Frequently Asked Questions

Does faster delivery apply to all study types?
TrialMax's faster eCOA improvements apply across the study complexity range. Timelines from study kick-off to UAT now run from as few as 15 working days for simple studies to under 5 weeks for complex ones. Studies with advanced requirements can exceed that range.
Does a faster timeline mean less flexibility in study design?
No. The timeline improvements come from tooling, automation, and library content, not from constraining what can be built. Sponsors retain the full flexibility of the TrialMax platform regardless of delivery timescale.
What types of complex study designs does TrialMax support?
TrialMax supports a wide range of eCOA requirements, from simple to complex. Complex features include, for example, detailed body maps, multi-component bleed diaries, country-specific medication tracking, complex food intake diaries, and branching logic with sophisticated scoring algorithms, among others.
How does TrialMax handle translations within these timelines?
Signant's validated translation library and API integration with its translation partner mean that translation readiness does not need to be an implementation bottleneck. For many studies, validated translations are available for immediate reuse, and new translations are completed on compressed timelines.

WHO IS SIGNANT HEALTH

Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant’s comprehensive eClinical solutions.  Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.